3D Medicines Inc
01244
Company Profile
Business description
3D Medicines Inc is an investment holding company. The company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products.It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China. Its commercialized product is Envita.
Contact
No. 3 and No. 5, Laiyang Road
Shandong Province, Shinan District
Qingdao
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
162
Stocks News & Analysis
stocks
Fears of deteriorating loan quality sends bank share plummeting
We maintain our fair value estimate despite unfavourable economic conditions.
stocks
Why it’s not all bad news for Flight Centre following downgrade
Despite an earnings downgrade, shares in FLT remain undervalued.
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
Our data shows buying into the IPO hype can be costly.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,964.20 | 1.20 | -0.01% |
| CAC 40 | 8,373.77 | 57.84 | -0.69% |
| DAX 40 | 24,690.50 | 304.33 | -1.22% |
| Dow JONES (US) | 51,920.62 | 71.72 | 0.14% |
| FTSE 100 | 10,426.21 | 103.68 | -0.98% |
| HKSE | 22,671.86 | 405.05 | -1.76% |
| NASDAQ | 25,358.60 | 118.03 | -0.46% |
| Nikkei 225 | 69,360.88 | 3,005.46 | -4.15% |
| NZX 50 Index | 13,495.24 | 2.19 | 0.02% |
| S&P 500 | 7,357.49 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,764.20 | 0.20 | 0.00% |
| SSE Composite Index | 4,027.26 | 93.02 | -2.26% |